Targeting the NLRP3 Inflammasome in Diabetic Nephropathy.

Ming Yang, Xi Wang, Yachun Han, Chenrui Li, Ling Wei, Jinfei Yang, Wei Chen, Xuejing Zhu, Lin Sun

Journal: Current medicinal chemistry 2022;28(42):8810-8824

PMID: 34225600

Abstract

Diabetic nephropathy (DN) is one of the most common complications of diabetes and the main cause of end-stage renal disease (ESRD). The inflammatory response plays a key role in the pathological process of DN. As the most deeply studied inflammasome, NLRP3 should not be overlooked in DN. Its abnormal activation accelerates DN progression. In this review, we summarize our understanding of the structural composition and activation factors of the NLRP3 inflammasome. Moreover, the relationship between NLRP3 inflammasome activation, and the potential of the NLRP3 inflammasome as a therapeutic target for DN will also be discussed.

Address: Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China.; Department of Nutrition, Xiangya Hospital, Central South University, Changsha, Hunan, China.

DOI: 10.2174/0929867328666210705153109

Link outs

Free resources

Medical:

https://medlineplus.gov/diabetickidneyproblems.htm...

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-HLA-B-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Diabetes Mellitus, Diabetic Nephropathies, Humans, Inflammasomes, NLR Family, Pyrin Domain-Containing 3 Protein